Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled seralutinib in pulmonary arterial hypertension
MOH_2023-09-12_012934Phase 3Recruiting
- Sponsor
- GB002, Inc.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Seralutinib plus background PAH therapy with Placebo plus background PAH therapy (2 arms). Primary endpoint: Change from baseline to week 24 in 6-minute walk distance. Started Sep 2023; status: recruiting.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2023-09-12_012934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-09-12_012934.